The intelligence that powers biotech's biggest decisions.

Biotechnology is moving toward programmable medicines, engineered biological systems, and increasingly personalized treatments. In March 2026, the FDA granted accelerated approval to Kresladi, the first gene therapy for severe leukocyte adhesion deficiency type I. The development demonstrates how genetic modification is creating treatment options for rare diseases with limited therapeutic alternatives.

Genomic research is producing increasingly large and complex datasets. The National Human Genome Research Institute provides more than USD 125 million annually for genomic data-science initiatives. WHO has also introduced principles covering the ethical collection, access, use, and sharing of human genomic information.

Our biotechnology practice tracks gene and cell therapies, recombinant products, antibodies, vaccines, RNA technologies, sequencing platforms, synthetic biology, bioinformatics, research tools, bioprocessing systems, licensing activity, and manufacturing strategies. Clients use this intelligence to size markets, evaluate pipelines, compare platforms, identify partners, prioritize technologies, support product development, and assess market-entry opportunities.